Putative circulating markers of the early and advanced stages of breast cancer identified by high-resolution label-free proteomics

Cancer Lett. 2013 Mar 1;330(1):57-66. doi: 10.1016/j.canlet.2012.11.020. Epub 2012 Nov 28.

Abstract

This study evaluated the plasmatic proteomic profile of breast cancer patients in the early (ED) and advanced (AD) stages, employing high-throughput proteomics. We identified 92 differentially expressed proteins in ED and 73 proteins in AD patients. Gelsolin, lumican, clusterin, SALL4 and PMS2, as well hTERT, TNF-α and GRHL3 were chosen for further investigation. ED presented augmented expression of GRHL3 and reduced circulating TNF-α with high expression of GRHL3 in tumors. AD displayed high TNF-α and a significant expression of PMS2 in tumors. These findings suggest processes enrolling stem cell division in ED, with TNF-α signaling and DNA mismatch repair in the advanced stage.

MeSH terms

  • Adult
  • Aged
  • Biomarkers, Tumor / blood*
  • Biomarkers, Tumor / genetics
  • Breast Neoplasms / blood*
  • Breast Neoplasms / genetics
  • Breast Neoplasms / pathology
  • Cell Line, Tumor
  • Female
  • Gene Expression Profiling
  • Humans
  • Middle Aged
  • Neoplasm Proteins / biosynthesis
  • Neoplasm Proteins / blood*
  • Neoplasm Staging
  • Prospective Studies
  • Proteomics / methods*

Substances

  • Biomarkers, Tumor
  • Neoplasm Proteins